The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea

Ho Sup Lee, Chang Ki Min, Je Jung Lee, Kihyun Kim, Seok Jin Kim, Dok Hyun Yoon, Hyeon Seok Eom, Hyewon Lee, Won Sik Lee, Ho Jin Shin, Ji Hyun Lee, Yong Park, Jae Cheol Jo, Young Rok Do, Yeung Chul Mun, Mark Hong Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In real clinical settings (not clinical trials), thalidomide has been accepted as maintenance therapy to patients with multiple myeloma (MM) because of the cost of drugs, the limitations of medical insurance, etc., in our country (South Korea). The purpose of this study was to evaluate the utility of thalidomide maintenance for improving survival in transplantation-eligible patients with MM in the real clinical field. Differences in survival rates were estimated in patients treated with or without thalidomide maintenance. The 3-year progression-free survival rates (PFS) of patients with and without maintenance, respectively, were 55.4 and 37.2 % (p = 0.005). The 3-year overall survival rates (OS) were 88.0 and 84.0 % (p = 0.105). No difference in 3-year OS after relapse or progression (OS2) was observed between the two groups (50.4 and 55.3 %, p = 0.661). The 3-year PFS of patients with and without maintenance therapy who had shown less than CR after ASCT were 68.4 and 23.3 % (p < 0.001). In conclusion, Thalidomide maintenance therapy showed longer PFS in real clinical practice, and long-term use of thalidomide did not interfere with the efficacy of salvage chemotherapy in patients who experienced progression or relapse after ASCT. In addition, thalidomide maintenance might be also useful for patients who have shown less than CR after ASCT.

Original languageEnglish
Pages (from-to)911-919
Number of pages9
JournalAnnals of Hematology
Volume95
Issue number6
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Thalidomide
Stem Cell Transplantation
Korea
Multiple Myeloma
Maintenance
Survival Rate
Disease-Free Survival
Recurrence
Republic of Korea
Drug Costs
Insurance
Therapeutics
Transplantation
Clinical Trials
Drug Therapy
Survival

Keywords

  • Maintenance
  • Multiple myeloma
  • Survival
  • Thalidomide
  • Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. / Lee, Ho Sup; Min, Chang Ki; Lee, Je Jung; Kim, Kihyun; Kim, Seok Jin; Yoon, Dok Hyun; Eom, Hyeon Seok; Lee, Hyewon; Lee, Won Sik; Shin, Ho Jin; Lee, Ji Hyun; Park, Yong; Jo, Jae Cheol; Do, Young Rok; Mun, Yeung Chul; Lee, Mark Hong.

In: Annals of Hematology, Vol. 95, No. 6, 01.05.2016, p. 911-919.

Research output: Contribution to journalArticle

Lee, HS, Min, CK, Lee, JJ, Kim, K, Kim, SJ, Yoon, DH, Eom, HS, Lee, H, Lee, WS, Shin, HJ, Lee, JH, Park, Y, Jo, JC, Do, YR, Mun, YC & Lee, MH 2016, 'The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea', Annals of Hematology, vol. 95, no. 6, pp. 911-919. https://doi.org/10.1007/s00277-016-2660-8
Lee, Ho Sup ; Min, Chang Ki ; Lee, Je Jung ; Kim, Kihyun ; Kim, Seok Jin ; Yoon, Dok Hyun ; Eom, Hyeon Seok ; Lee, Hyewon ; Lee, Won Sik ; Shin, Ho Jin ; Lee, Ji Hyun ; Park, Yong ; Jo, Jae Cheol ; Do, Young Rok ; Mun, Yeung Chul ; Lee, Mark Hong. / The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. In: Annals of Hematology. 2016 ; Vol. 95, No. 6. pp. 911-919.
@article{58f892d45aed473d950e8c576a8c964e,
title = "The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea",
abstract = "In real clinical settings (not clinical trials), thalidomide has been accepted as maintenance therapy to patients with multiple myeloma (MM) because of the cost of drugs, the limitations of medical insurance, etc., in our country (South Korea). The purpose of this study was to evaluate the utility of thalidomide maintenance for improving survival in transplantation-eligible patients with MM in the real clinical field. Differences in survival rates were estimated in patients treated with or without thalidomide maintenance. The 3-year progression-free survival rates (PFS) of patients with and without maintenance, respectively, were 55.4 and 37.2 {\%} (p = 0.005). The 3-year overall survival rates (OS) were 88.0 and 84.0 {\%} (p = 0.105). No difference in 3-year OS after relapse or progression (OS2) was observed between the two groups (50.4 and 55.3 {\%}, p = 0.661). The 3-year PFS of patients with and without maintenance therapy who had shown less than CR after ASCT were 68.4 and 23.3 {\%} (p < 0.001). In conclusion, Thalidomide maintenance therapy showed longer PFS in real clinical practice, and long-term use of thalidomide did not interfere with the efficacy of salvage chemotherapy in patients who experienced progression or relapse after ASCT. In addition, thalidomide maintenance might be also useful for patients who have shown less than CR after ASCT.",
keywords = "Maintenance, Multiple myeloma, Survival, Thalidomide, Transplantation",
author = "Lee, {Ho Sup} and Min, {Chang Ki} and Lee, {Je Jung} and Kihyun Kim and Kim, {Seok Jin} and Yoon, {Dok Hyun} and Eom, {Hyeon Seok} and Hyewon Lee and Lee, {Won Sik} and Shin, {Ho Jin} and Lee, {Ji Hyun} and Yong Park and Jo, {Jae Cheol} and Do, {Young Rok} and Mun, {Yeung Chul} and Lee, {Mark Hong}",
year = "2016",
month = "5",
day = "1",
doi = "10.1007/s00277-016-2660-8",
language = "English",
volume = "95",
pages = "911--919",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea

AU - Lee, Ho Sup

AU - Min, Chang Ki

AU - Lee, Je Jung

AU - Kim, Kihyun

AU - Kim, Seok Jin

AU - Yoon, Dok Hyun

AU - Eom, Hyeon Seok

AU - Lee, Hyewon

AU - Lee, Won Sik

AU - Shin, Ho Jin

AU - Lee, Ji Hyun

AU - Park, Yong

AU - Jo, Jae Cheol

AU - Do, Young Rok

AU - Mun, Yeung Chul

AU - Lee, Mark Hong

PY - 2016/5/1

Y1 - 2016/5/1

N2 - In real clinical settings (not clinical trials), thalidomide has been accepted as maintenance therapy to patients with multiple myeloma (MM) because of the cost of drugs, the limitations of medical insurance, etc., in our country (South Korea). The purpose of this study was to evaluate the utility of thalidomide maintenance for improving survival in transplantation-eligible patients with MM in the real clinical field. Differences in survival rates were estimated in patients treated with or without thalidomide maintenance. The 3-year progression-free survival rates (PFS) of patients with and without maintenance, respectively, were 55.4 and 37.2 % (p = 0.005). The 3-year overall survival rates (OS) were 88.0 and 84.0 % (p = 0.105). No difference in 3-year OS after relapse or progression (OS2) was observed between the two groups (50.4 and 55.3 %, p = 0.661). The 3-year PFS of patients with and without maintenance therapy who had shown less than CR after ASCT were 68.4 and 23.3 % (p < 0.001). In conclusion, Thalidomide maintenance therapy showed longer PFS in real clinical practice, and long-term use of thalidomide did not interfere with the efficacy of salvage chemotherapy in patients who experienced progression or relapse after ASCT. In addition, thalidomide maintenance might be also useful for patients who have shown less than CR after ASCT.

AB - In real clinical settings (not clinical trials), thalidomide has been accepted as maintenance therapy to patients with multiple myeloma (MM) because of the cost of drugs, the limitations of medical insurance, etc., in our country (South Korea). The purpose of this study was to evaluate the utility of thalidomide maintenance for improving survival in transplantation-eligible patients with MM in the real clinical field. Differences in survival rates were estimated in patients treated with or without thalidomide maintenance. The 3-year progression-free survival rates (PFS) of patients with and without maintenance, respectively, were 55.4 and 37.2 % (p = 0.005). The 3-year overall survival rates (OS) were 88.0 and 84.0 % (p = 0.105). No difference in 3-year OS after relapse or progression (OS2) was observed between the two groups (50.4 and 55.3 %, p = 0.661). The 3-year PFS of patients with and without maintenance therapy who had shown less than CR after ASCT were 68.4 and 23.3 % (p < 0.001). In conclusion, Thalidomide maintenance therapy showed longer PFS in real clinical practice, and long-term use of thalidomide did not interfere with the efficacy of salvage chemotherapy in patients who experienced progression or relapse after ASCT. In addition, thalidomide maintenance might be also useful for patients who have shown less than CR after ASCT.

KW - Maintenance

KW - Multiple myeloma

KW - Survival

KW - Thalidomide

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84962757622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962757622&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2660-8

DO - 10.1007/s00277-016-2660-8

M3 - Article

VL - 95

SP - 911

EP - 919

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 6

ER -